ArticleCalcified tissue international2026
Generation and Characterization of an Osteoclastic Cell Model of Gaucher's Bone Disease.
Article in Calcified tissue international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Gaucher disease (GD) is caused by recessive mutations in the GBA1 gene (Glucosylceramidase beta 1) generating lysosomal accumulation of glucosylceramides. Bone phenotypes related to GD include Erlenmeyer flask deformity, osteosclerosis, osteonecrosis, osteopenia, and bone pain. Lysosomes modulate osteoclast differentiation, playing a fundamental role in osteoclastogenesis and bone resorption. However, the role of GBA1 mutations in the osteoclast function remains poorly understood. We aimed to generate and characterize an in vitro osteoclast cell model of GD. The Gba1 gene was knocked out with CRISPR/Cas9 in the murine macrophage cell line RAW264.7. One RAW-Gba1KO clone displaying no GBA1 enzymatic activity was selected. Non-edited RAW264.7 cells were used as controls (wt). Expression of osteoclast biomarkers, Rank, Trap, Nfatc1, and pro-cathepsin K/cathepsin K as well as activity of TRAP protein and bone resorption were assessed. RAW-Gba1KO cells showed reduced expression of the osteoclast differentiation markers Rank and Nfatc1, suggesting that osteoclast differentiation is delayed or impaired compared with wt cells. Despite this, KO cells exhibited higher expression of Trap and cathepsin K, indicating enhanced osteoclast activity. Functional assays confirmed this finding, showing significantly increased TRAP activity and bone resorption in KO cells during differentiation. Additionally, KO cells displayed elevated levels of cathepsin K and pro-cathepsin K, particularly before differentiation, which may contribute to the increased TRAP activation. In conclusion, lack of Gba1 activity induced changes in our osteoclast model which enhanced its bone resorption potential, demonstrating a major intrinsic osteoclastic defect in Gaucher disease of bone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.